18F-FDG and 18F-florbetapir PET in clinical practice: Regional analysis in mild cognitive impairment and alzheimer disease

Clinical Nuclear Medicine

Volumn 40, Issue 2, 2015, Pages e111-e116

  Bailly, Matthieu ^a,b   Ribeiro, Maria Joao Santiago ^b,c   Vercouillie, Johny ^c   Hommet, Caroline ^b,c   Gissot, Valérie ^d   Camus, Vincent ^b,c   Guilloteau, Denis ^a,c,d  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^b CHU BRETONNEAU   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

18F AV45; 18F FDG; Alzheimer disease; florbetapir; MCI; PET

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; FRANCE; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; MALE; METABOLIC RATE; MILD COGNITIVE IMPAIRMENT; NEUROANATOMY; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS CORTEX; TEMPORAL LOBE; VERY ELDERLY; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; EVALUATION STUDY; METABOLISM; MIDDLE AGED; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; CASE-CONTROL STUDIES; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84921474934     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000666     Document Type: Article

References (43)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319
2. Rowe CC, Ng S, Ackermann U, Gong SJ, et al. Imaging beta-Amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725
3. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PETamyloid ligand [#sup#11#/sup#C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575-1580
4. Pike KE, Savage G, Villemagne VL, et al. Beta-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844
5. Mintun MA, Larossa GN, Sheline YI, et al. [#sup#11#/sup#C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67: 446-452
6. Barthel H, Sabri O. Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26(Suppl 3):117-121
7. Herholz K. Imaging cerebral amyloid plaques: clinical perspective. Lancet Neurol. 2012;11:652-653
8. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-Amyloid. Semin Nucl Med. 2011;41:283-299
9. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-Amyloid pathology. JAMA. 2011;305:275-283
10. Camus V, Payoux P, Barre L, et al. Using PET with #sup#18#/sup#F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621-631
11. Chetelat G. La neuro-imagerie au service de la maladie d'Alzheimer. Med Sci. 2011;27:193-198
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944
13. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216
14. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308
15. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127
16. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746
17. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269
18. Mosconi L, McHugh PF. FDG-And amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging. 2011;55: 250-264
19. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98:10966-10971
20. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:811-822
21. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cin-gulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94
22. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of #sup#18#/sup#F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878-886
23. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly inthe cerebellum in Alzheimer's disease. Am J Pathol. 1989;135:309-319
24. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086-2092
25. Benson DF, Kuhl DE, Hawkins RA, et al. The fluorodeoxyglucose #sup#18#/sup#F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol. 1983;40:711-714
26. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529-539
27. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolisminMCI and AD: automated FDG-PET image analysis. Neurology. 2005;64:1860-1867
28. Nestor PJ, Fryer TD, Ikeda M, et al. Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci. 2003;18:2663-2667
29. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113
30. Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344:895
31. Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008;35:2169-2181
32. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [#sup#11#/sup#C]PIB and [#sup#18#/sup#F]FDG PET study. Neurology. 2007;68: 501-508
33. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678
34. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456-1465
35. Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134: 1077-1088
36. Small GW, Kepe V, Ercoli LM, et al. PETof brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652-2663
37. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-1411
38. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand #sup#18#/sup#F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920
39. La Joie R, Perrotin A, Barre L, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-Amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci. 2012;32:16265-16273
40. Wolk DA, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923-926
41. Rodrigue KM, Kennedy KM, Devous MD Sr, et al. Beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387-395
42. Saint-Aubert L, Barbeau EJ, Peran P, et al. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res. 2013;3:43
43. Cselényi Z, Eriksdotter Jönhagen M, Forsberg A, et al. Clinical validation of #sup#18#/sup#F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med. 2012; 53:415-424